The AI Innovation Lab in London and Mainz, Germany will be formed to apply the latest artificial intelligence and machine-learning technologies to develop novel immunotherapies for a range of cancers and infectious diseases, including COVID-19. The collaboration will combine InstaDeep's advanced capabilities in artificial intelligence, machine learning, and digitalization with BioNTech's expertise in precision immunotherapies.

One of the key research focus areas of the lab will be development of next generation vaccines and biopharmaceuticals for the treatment of cancer and prevention and treatment of infectious diseases. This includes applying InstaDeep's DeepChain protein design platform to engineer new messenger RNA sequences for protein targets. The companies plan to generate insights from proprietary patient meta datasets and optimize manufacturing and supply chain processes by utilizing AI and machine-learning applications.

Pfizer, BioNTech to submit EUA request
Pfizer and BioNTech will submit a request on November 20 to the U.S. Food and Drug Administration for emergency use authorization (EUA) of their messenger...

Pfizer, BioNTech just days away from applying for EUA for COVID-19 vaccine
Pfizer and BioNTech have passed another milestone in their effort to deliver a vaccine for the SARS-CoV-2 virus. The companies on November 18 reported...

Pfizer, BioNTech finalize supply deal with EU for COVID-19 vaccine
Pfizer and BioNTech, developers of BNT162b2, a messenger RNA-based SARS-CoV-2 vaccine candidate, have reached an agreement with the European Commission...

Pfizer, BioNTech tout positive results for COVID-19 vaccine
Pfizer and BioNTech have released results from a phase III clinical trial evaluating their messenger RNA-based vaccine candidate, BNT162b2, demonstrating...

EMA to review BioNTech, Pfizer's SARS-CoV-2 vaccine
The European Medicines Agency (EMA) has accepted rolling review of BioNTech and Pfizer's SARS-CoV-2 vaccine candidate BNT162b2 based on preclinical and...